Skip to main content
Category

Funding

AdvocacyFunding

EGFR Resisters and LCRF Research Partnership

*November 2021* RESEARCH=SURVIVAL! As you may know, we have increased our goal to $225K to keep fundraising for additional research projects that we will fund through our collaboration with LCRF in 2022. These research projects will be dedicated to EGFR+ lung cancer and hopefully lead to discoveries that will provide…
laurabbook@gmail.com
November 12, 2021
FundingPartnersResearchTreatments

EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award

*February 2021* WASHINGTON, Feb. 19, 2021 /PRNewswire/ -- Patient group EGFR Resisters and LUNGevity Foundation today announced the 2021 recipients of the first EGFR Resisters/LUNGevity Lung Cancer Research Award. This award program, driven by EGFR Resisters—a grassroots patient-led group that has 2,500+ patients and caregivers from 75+ countries—supports critical research that seeks to…
cece
June 19, 2021
FundingResearch

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center is being established with a $5 million gift from Winston Chen,…
laurabbook@gmail.com
January 18, 2020